Enhancing care and managing side effects in patients receiving bortezomib.
Colson
Kathleen
K
Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D019468:Disease Management; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007700:Kinetics; D009859:Oncology Nursing; D010353:Patient Education as Topic; D010976:Platelet Count; D011719:Pyrazines / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D011788:Quality of Life; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib